A Phase 3 interventional study of Ongericimab and Placebo in Heterozygous Familial Hypercholesterolemia, sponsored by Shanghai Junshi Bioscience Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-03-18.
Sponsored by Shanghai Junshi Bioscience Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Hyperlipoproteinemia Type II with a site in China — 13 open to participants now, 13 under way, 7 of them phase 3. Hyperlipoproteinemia Type II · China.
Among the 24 studies in Hyperlipoproteinemia Type II with a site in China, this one is the 12th largest by enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2021, is one of 13 in phase 3, and was the 9th registered.
251 studies on the registry are indexed under Hyperlipoproteinemia Type II; 57 are open to participants now.
Browse Hyperlipoproteinemia Type II studies →13 of the 24 studies in Hyperlipoproteinemia Type II with a site in China are open now. Recruiting first, the newest first:
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18+
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18+ · Healthy volunteers
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18+
Merck Sharp & Dohme LLC · Sites in China, United States, Australia and 17 more countries
Ages 6–17
Children's Hospital of Fudan University · Sites in China
Ages 1–3
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 37 Hyperlipoproteinemia Type II studies recruiting now, 17 (46%) set no upper age limit and 16 (43%) stop at 75 or younger; 17 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 3 14
First in 2018; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 135 is close to the median of 131 across 180 interventional studies indexed under Hyperlipoproteinemia Type II.
Median enrollment 142 across the 22 interventional studies, 8,064 across the 2 observational. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 24 have an industry lead sponsor. The 10 most frequent:
Shanghai Junshi Bioscience Co., Ltd. is the lead sponsor of 100 studies on the registry; 20 are open to participants now.
Shanghai Junshi Bioscience Co., Ltd. has 1 study filed under Hyperlipoproteinemia Type II — fewer than ten, so there is no comparison to draw.
3 of the studies in Hyperlipoproteinemia Type II with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05043181Tang-Du HospitalExosome-based Nanoplatform for Ldlr mRNA Delivery in FH | 2026-12 |
| NCT07695597CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.A Study of SYH2070 Injection in Participants With Mixed Hyperlipidemia | 2027-04-30 |
| NCT07353398Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineEarly-phase Study of ART002g1 Injection in HeFH: Safety, Tolerability and Preliminary Efficacy | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 24 studies in Hyperlipoproteinemia Type II with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
JS002 is a recombinant human anti-PCSK9 monoclonal antibody.The study is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study in Chinese patients with heterozygous familial hypercholesterolemia (HeFH). Objective To evaluate the efficacy and safety of JS002 150 mg (Q2W) and 450 mg (Q4W) subcutaneous injection (SC).
A randomized, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety of JS002 in patients with heterozygous familial hypercholesterolemia. 120 subjects are planned to be enrolled. Each subject is required a maximum of 6 weeks of screening, 24 weeks of treatment, and 8 weeks of follow-up. To evaluate the lipid-lowering efficacy of subcutaneous injection of JS002 at 24 weeks compared with placebo in heterozygous familial hypercholesterolemia patients under optimized lipid lowing therapy . Subjects meeting the study inclusion criteria will be randomly assigned in a 2:1:2:1 ratio to JS002 150 mg Q2W or JS002 450 mg Q4W or matched placebo to receive the study drug (JS002) or placebo subcutaneously for 24 weeks.
treatment cohorts: JS002 150mg Cohort:JS002 150mg or placebo treatment(JS002 :Placebo=2:1) Q2W JS002 450mg Cohort:JS002 450mg or placebo treatment(JS002 :Placebo=2:1)Q4W
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
40 patients will be enrolled in this arm
Biological: Ongericimab
20 patients will be enrolled in this arm
Drug: Placebo
40 patients will be enrolled in this arm
Biological: Ongericimab
20 patients will be enrolled in this arm
Drug: Placebo
Administered by subcutaneous injection
Also known as: JS002
Administered by subcutaneous injection
Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24
LDL-C was quantified using the enzymatic colorimetric assay
Time frame: Baseline and week 24
Absolute Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24
LDL-C was quantified using the enzymatic colorimetric assay
Time frame: Baseline and Week 24
Percentage changes From Baseline in the Total Cholesterol at week 24
TC was quantified using the enzymatic colorimetric assay
Time frame: Baseline and Week 24
Absolute changes From Baseline in the Total Cholesterol at week 24
TC was quantified using the enzymatic colorimetric assay
Time frame: Baseline and Week 24
Percentage changes From Baseline in Non-HDL-C at Week 24
Non-HDL-C was quantified using the Calculation,TC minus HDL-C
Time frame: Baseline and Week 24
Absolute changes From Baseline in Non-HDL-C at Week 24
Non-HDL-C was quantified using the Calculation,TC minus HDL-C
Time frame: Baseline and Week 24
Percentage changes From Baseline in Apo B at Week 24
Apo B was quantified using the turbidimetric immunoassay(TIA)
Time frame: Baseline and Week 24
Absolute changes From Baseline in Apo B at Week 24
Apo B was quantified using the turbidimetric immunoassay(TIA)
Time frame: Baseline and Week 24
Percentage changes From Baseline in Lp(a) at Week 24
Lp(a) was quantified using the turbidimetric immunoassay(TIA)
Time frame: Baseline and Week 24
Absolute changes From Baseline in Lp(a) at Week 24
Lp(a) was quantified using the turbidimetric immunoassay(TIA)
Time frame: Baseline and Week 24
Percentage changes From Baseline in HDL-C at Week 24
HDL-C was quantified using the enzymatic colorimetric assay
Time frame: Baseline and Week 24
Absolute changes From Baseline in HDL-C at Week 24
HDL-C was quantified using the enzymatic colorimetric assay
Time frame: Baseline and Week 24
Percentage changes From Baseline in Apo A1 at Week 24
Apo A1 was quantified using the turbidimetric immunoassay(TIA)
Time frame: Baseline and Week 24
Absolute changes From Baseline in Apo A1 at Week 24
Apo A1 was quantified using the turbidimetric immunoassay(TIA)
Time frame: Baseline and Week 24
Percentage changes From Baseline in TG at Week 24
TG was quantified using the enzymatic colorimetric assay
Time frame: Baseline and Week 24
Absolute changes From Baseline in TG at Week 24
TG was quantified using the enzymatic colorimetric assay
Time frame: Baseline and Week 24
The ratio of TC/HDL - C
Calculation
Time frame: Baseline and Week 24
The ratio of Apo B/Apo A1
Calculation
Time frame: Baseline and Week 24
Percentage of Participants With 50% or Greater Reduction in LDL-C From Baseline at Week 24
Calculation
Time frame: Baseline and Week 24
Number of subjects who develop detectable anti-drug antibodies (ADAs)
ADA was quantified using the Bridging-ECLIA
Time frame: from baseline to 32 weeks
Ran from Dec 2021 to primary completion in May 2023, 16 months.
Of 33 phase 3 interventional studies under Hyperlipoproteinemia Type II, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 34. This study's 16 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ongericimab
Hyperlipoproteinemia Type II →
Shanghai Junshi Bioscience Co., Ltd. →